CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0002
+0.000015 (8.11%)
At close: May 5, 2026
CNBX Pharmaceuticals Employees
CNBX Pharmaceuticals had 1 employees as of February 28, 2026. The number of employees did not change since the number was reported on August 31, 2025.
Employees
1
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$367,653
Market Cap
295.15K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Feb 28, 2026 | 1 | 0 | - |
| Aug 31, 2025 | 1 | -1 | -50.00% |
| Aug 31, 2024 | 2 | 0 | - |
| Aug 31, 2023 | 2 | -3 | -60.00% |
| Aug 31, 2022 | 5 | -5 | -50.00% |
| Aug 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Altamira Therapeutics | 11 |
| Innovation Pharmaceuticals | 4 |
| GB Sciences | 2 |
| Actavia Life Sciences | 1 |
| Regen BioPharma | 1 |
| Bio-Path Holdings | 1 |
CNBX Pharmaceuticals News
- 3 years ago - CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - PRNewsWire
- 3 years ago - CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - PRNewsWire
- 3 years ago - CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - PRNewsWire
- 3 years ago - CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - PRNewsWire
- 3 years ago - CNBX Pharmaceuticals Announces New Patent Granted in Australia - PRNewsWire
- 4 years ago - CNBX Pharmaceuticals Granted Patent in Hong Kong - PRNewsWire
- 4 years ago - Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals - PRNewsWire
- 4 years ago - CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials - PRNewsWire